Aniracetam 500mg - 50 capsules

Aniracetam is a powerful nootropic belonging to the racetam family, which is known for its benefits in improving cognitive function. Derived from piracetam, aniracetam is more fat-soluble, which allows it to be absorbed and act more quickly in the nervous system.

Why is it considered a nootropic? A nootropic is a substance that improves cognitive function, such as memory, creativity, and motivation, in healthy individuals, without causing harmful or significant side effects. Aniracetam fits into this category because it has been consistently shown to improve cognition and mental performance.

Mechanism of action : It is known to act by modulating AMPA receptors, a specific type of glutamate receptor in the brain. By influencing these receptors, aniracetam can enhance synaptic neurotransmission, resulting in improved neuronal communication. Additionally, it is also believed to increase the release of acetylcholine in the hippocampus, a brain region vital for memory and learning.

Benefits of Aniracetam :

1. Memory Enhancement : Aniracetam is widely recognized for enhancing memory, aiding in short- and long-term retention and retrieval of information.
2. Enhanced concentration and attention : Users have reported a greater ability to focus on tasks and maintain attention for long periods.
3. Mood elevation : Aniracetam may act as an anxiolytic, helping to reduce anxiety and stress levels, and promoting an overall sense of well-being.
4. Sensory stimulation : Some users experience a sharper perception of their surroundings, including brighter colors, clearer sounds, and an improved tactile experience.
5. Reduced social anxiety : It has been shown to be beneficial for people who suffer from social anxiety, allowing for greater confidence and ease in social interactions.
6. Neuroprotection : There is evidence that aniracetam may offer neuroprotective properties, safeguarding the brain against cognitive decline and potential neuronal damage.
7. Increased creativity : By improving the fluidity of thinking, many users have reported an increase in their creative capacity and problem-solving skills.
8. Improved learning ability : Facilitates the acquisition of new information and improves the brain's ability to adapt and learn from new experiences.
9. Improvement in verbal communication : Aniracetam has been observed to improve verbal fluency, making communication and the expression of ideas easier.
10. Improvement in spatial perception : The ability to understand and orient yourself in space is enhanced, which is beneficial in tasks that require spatial skills.

Absorption : Due to its fat-soluble nature, aniracetam is better absorbed when taken with fatty foods or a fat source. This lipid solubility means that it can cross the blood-brain barrier more effectively when consumed alongside fats.

Therefore, if you are considering taking aniracetam as a supplement, it may be beneficial to take it with a meal that contains healthy fats, such as avocados, nuts, olive oil, or fatty fish such as salmon. Alternatively, some people choose to take aniracetam with an oil supplement, such as fish oil or MCT oil, to maximize its absorption.

Adverse Effects: Aniracetam is generally well tolerated by most people, but as with any substance, it may cause side effects in some individuals. Possible adverse effects of aniracetam include:

1. Headache: This is a side effect commonly associated with racetams. It is often suggested to supplement with a choline source (such as citicoline or Alpha GPC) to help mitigate this effect.
2. Anxiety or restlessness: Although aniracetam is often taken to reduce anxiety, in some people it can have the opposite effect, especially at higher doses.
3. Gastrointestinal problems: These may include nausea, diarrhea, or stomach upset.
4. Dizziness or vertigo: Some users have reported feeling dizzy after taking aniracetam.
5. Insomnia: Particularly if taken later in the day, aniracetam may interfere with sleep in some people.

Contraindications:

1. Liver conditions: Aniracetam is metabolized in the liver, so those with liver problems should proceed with caution and possibly avoid the use of aniracetam.
2. Drug interaction: As with other nootropics, it is essential to consult a doctor before combining aniracetam with other medications, especially those that have an effect on the central nervous system.
3. Pregnancy and breast-feeding: The safety of aniracetam during pregnancy and breast-feeding has not been clearly established. It is advisable that pregnant or lactating women avoid use unless otherwise determined by a healthcare professional.
4. Coagulation disorders: Although not a widely reported side effect for aniracetam, other racetams have shown influence on blood clotting. Those with clotting disorders should proceed with caution.

It is important to emphasize that, while aniracetam has a variety of potential benefits, the effects may vary between individuals. It is always essential that users do their own research and, if possible, consult with a health professional before incorporating it into their routine.

More information about Aniracetam and its dosage: https://nootropicsexpert.com/aniracetam/

References on studies:

[i] Malykh AG, Sadaie MR “Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.” Drugs . 2010 Feb 12;70(3):287-312. ( source )

[ii] Gabryel B., Chalimoniuk M., Małecki A., Strosznajder J. “Effect of aniracetam on phosphatidylinositol transfer protein alpha in cytosolic and plasma membrane fractions of astrocytes subjected to simulated ischemia in vitro.” Pharmacological Reports 2005 Sep-Oct;57(5):664-9. ( source )

[iii] Isaacson JS, Nicoll RA “Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus” Proceedings of the National Academy of Sciences in the United States of America vol. 88, pp. 10936-10940, December 1991 ( source )

[iv] Zhao X., Kuryatov A., Lindstrom JM, Yeh JZ, Narahashi T. “Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.” Molecular Pharmacology 2001 Apr;59(4):674-83. ( source )

[v] Purves D., Augustine GJ, Fitzpatrick D., et al., editors. “Glutamate Receptors” Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates; 2001. ( source )

[vi] Roncan G. “Human Pharmacokinetics of Aniracetam” Springer – Drug Investigation June 1993, Volume 5, Supplement 1, pp 68-72 ( source )

[vii] Gouliaev AH, Senning A., “Piracetam and other structurally related nootropics” Brain Research Reviews 19 (1994) 180-222 ( source )

[viii] Nakamura K. “Aniracetam: Its Novel Therapeutic Potential in Cerebral Dysfunctional Disorders Based on Recent Pharmacological Discoveries” CNS Drug Reviews 2002 Neva Press, Branford, Connecticut Vol. 8, No. 1, pp. 70–89 (source )

[ix] Testa B., Mayer JM (1 August 2003). Hydrolysis in Drug and Prodrug Metabolism . John Wiley & Sons. pp. 109–. ISBN 978-3-906390-25-3.

[x] Nakamura K., Kurasawa M. “Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.” European Journal of Pharmacology 2001 May 18;420(1):33-43. ( source )

[xi] Koliaki CC, Messini C., Tsolaki M. “Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study” CNS Neuroscience & Therapeutics Volume 18, Issue 4, pages 302–312, April 2012 ( source )

[xii] Nakamura K, Tanaka Y. “Antidepressant-like effects of aniracetam in aged rats and its mode of action.” Psychopharmacology (Berlin) . 2001 Nov;158(2):205-12. ( source )

[xiii] Cumin R., Bandle EF, Gamzu E., Haefely WE “Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.” Psychopharmacology (Berlin) 1982;78(2):104-11. ( source )

[xiv] Wijayawardhane .1, Shonesy BC, Vaglenova J., Vaithianathan T., Carpenter M., Breese CR, Dityatev A., Suppiramaniam V. “Postnatal aniracetam treatment improves prenatal ethanol induced attenuation of AMPA receptor-mediated synaptic transmission.” Neurobiology of Disease 2007 Jun;26(3):696-706. ( source )